Analysis

Kyverna Therapeutics, Inc. (KYTX) Stock Analysis

Kyverna Therapeutics, Inc. investors can use 6ix to track stock price context, company news, investor events, webinar replays, and AI-assisted analysis connected to KYTX.

websiteKYTX/analysis/KYTX

Kyverna Therapeutics, Inc.

Kyverna Therapeutics, Inc. investors can use 6ix to track stock price context, company news, investor events, webinar replays, and AI-assisted analysisconnected to KYTX.

Stock profile

Ticker

KYTX

Asset type

Stock

Market cap

$490.6M

Sector

Health Technology

Industry

Biotechnology

Currency

USD

Ticker listings

Kyverna Therapeutics, Inc. may appear across multiple exchanges or ticker formats. 6ix consolidates those listings around the canonical analysis page for discovery.

  • KYTX primary listing

Latest Kyverna Therapeutics, Inc. news

Kyverna Therapeutics Highlights Updated Miv-cel Data at EULAR Demonstrating Substantial Reduction in Disease Activity in ACPA-Positive, T...

Kyverna Therapeutics Highlights Updated Miv-cel Data at EULAR Demonstrating Substantial Reduction in Disease Activity in ACPA-Positive, Treatment Refractory Rheumatoid Arthritis

Kyverna Therapeutics Names Greg Martini as Chief Financial Officer

Veteran biopharma leader joins to help lead Kyverna’s next phase of commercial growthEMERYVILLE, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYT...

Kyverna Therapeutics Announces Initiation of Rolling SPS BLA Submission and Reports First Quarter 2026 Financial Results

Positive pre-BLA meeting with FDA alignment reached on KYSA-8 single-arm trial in stiff person syndrome (SPS); rolling BLA submission initiated Miv-cel pivotal trial primary ana...

Kyverna Therapeutics Appoints Nadia Dac, Seasoned Commercial Leader in Neurology and Rare Disease, as Chief Commercial Officer

Ms. Dac brings more than 30 years of experience successfully executing product launches and scaling commercial organizations for a range of therapeutic areasEMERYVILLE, Calif., ...

Kyverna Presents Registrational Trial Primary Analysis for Miv-cel in Stiff Person Syndrome Demonstrating Statistically Significant, Dura...

Single-dose of miv-cel achieved robust and durable improvements in mobility, reversed disability scores, and eliminated the need for chronic immunotherapies –

Research sections

Valuation

Review valuation context for Kyverna Therapeutics, Inc..

Future growth

Review future growth context for Kyverna Therapeutics, Inc..

Past performance

Review past performance context for Kyverna Therapeutics, Inc..

Financial health

Review financial health context for Kyverna Therapeutics, Inc..

Dividend

Review dividend context for Kyverna Therapeutics, Inc..

Management

Review management context for Kyverna Therapeutics, Inc..

Ownership

Review ownership context for Kyverna Therapeutics, Inc..

Other information

Review other information context for Kyverna Therapeutics, Inc..

Community

Review community context for Kyverna Therapeutics, Inc..